SynthesisMycoses2022
Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: A systematic review and meta-analysis.
Synthesis in Mycoses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Guideline
- Pooled it
- Real-world study of effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- In Vitro and In Silico Investigations of Antifungal Activity of Ethyl Acetate Extracts of Various Species of Swertia Against Aspergillus fumigatus.Chemistry & biodiversity · 2026Article
- Nitroxoline exerts potent anti-Antimicrobial agents and chemotherapy · 2026Article
- Article
- A machine learning-based risk prediction tool for early identification of invasive pulmonary aspergillosis in immunocompetent patients: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Current Evidence on Voriconazole Exposure and Individualized Therapy for Aspergillosis.Infection and drug resistance · 2026Review
- Machine learning for early screening of influenza A-associated invasive pulmonary aspergillosis in hospitalized patients: a real-world study.Frontiers in cellular and infection microbiology · 2026Article
- Development and validation of an interpretable machine learning model for the early diagnosis of invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Dose-response relationship of pre-ICU corticosteroids and influenza-associated pulmonary aspergillosis: a multicenter target trial emulation.Annals of intensive care · 2026Article
- Diagnostic utility of endotracheal aspirate galactomannan for invasive pulmonary aspergillosis in ICU patients.Le infezioni in medicina · 2026Article
- Secondary fungal infections in severe acute viral diseases: clinical features and underlying immune mechanisms.Frontiers in microbiology · 2026Review
- Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm.Diagnostics (Basel, Switzerland) · 2025Review
- VAPA strikes the patient again!Medical mycology case reports · 2025Article
- Risk and prognostic patterns of viral-associated invasive pulmonary aspergillosis: impact of corticosteroid and antibiotic exposure in non-neutropenic hosts.Journal of thoracic disease · 2025Article
- Influenza-related invasive pulmonary aspergillosis in an infectious disease ward at a pulmonary referral center in Iran.BMC infectious diseases · 2025Article
- Pulmonary Aspergillosis in Immunocompromised Critically Ill Patients: Prevalence, Risk Factors, Clinical Features and Diagnosis-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosis.Annals of clinical microbiology and antimicrobials · 2025Article
- Retrospective Analysis of Fungal Isolations in Patients on Veno-Venous Extracorporeal Membrane Oxygenation: The Multicenter RANGER STUDY 2.0.Journal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAn increasing number of cases of invasive pulmonary aspergillosis (IPA) complicating influenza have been described. We performed a meta-analysis to estimate the incidence, risk factors and outcomes of IPA in patients with influenza.
methodsA systematic search was conducted in the PubMed, EMBASE and Cochrane Library databases from their inception to 31 August 2021 for eligible studies. Data on the incidence and risk factors of and mortality due to IPA in influenza patients were pooled using a random-effects model. Sensitivity analyses restricted to severe influenza requiring intensive care unit (ICU) support and multiple subgroup analyses were performed.
resultsFourteen studies involving 6024 hospitalised patients with influenza were included. IPA was estimated to occur in 10% of influenza patients, with a mortality rate of 52%. Similar incidence (11%) and mortality (54%) estimates for IPA were observed in the sensitivity analysis including severe cases requiring ICU support. Subgroup analysis by geographical location showed a similar IPA rate between European (10%) and non-European (11%) studies. The IPA rate in the subset of nine studies using the modified AspICU criteria was 13%. Most subgroup analyses showed ≥50% mortality in IPA patients. Several predictors for IPA susceptibility were identified, including male sex, smoking history, chronic lung disease, influenza A (H1N1), severe conditions requiring supportive therapy, corticosteroid use before admission, solid organ transplant and haematological malignancy.
conclusionsThe IPA is common in individuals with severe influenza, and the prognosis is particularly poor. Influenza patients, especially those with high-risk factors, should be thoroughly screened for IPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.